We advised the underwriters in connection with the SEC-registered equity offering

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of an aggregate of 17,250,000 shares of common stock of Precigen, Inc. for $129.4 million before underwriting discounts and estimated expenses of the offering. The common stock of Precigen, Inc. is listed on the Nasdaq Capital Market under the symbol “PGEN.”

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases.

The Davis Polk corporate team included partners John B. Meade and Yasin Keshvargar, counsel Joseph S. Payne and associates Arisa Akashi and Shaoting Qin. The intellectual property and technology transactions team included partner David R. Bauer, counsel Bonnie Chen and associate Brette L. Trost. Counsel Kiara L. Rankin and associate Shay Moyal provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post